SOURCE: Amarillo Biosciences, Inc.

April 11, 2006 16:11 ET

Amarillo Biosciences Nominates Thomas D'Alonzo, Former President, Glaxo, Inc., and Thomas Ulie, CEO, First Island Capital, to Its Board of Directors

AMARILLO, TX -- (MARKET WIRE) -- April 11, 2006 -- Amarillo Biosciences, Inc. (ABI) (OTC BB: AMAR) today announced that it has nominated Messrs. Thomas W. D'Alonzo, Esq. and Thomas Ulie, CFA, to its Board of Directors. Shareholders will formally vote on these nominations at ABI's Annual Shareholders' Meeting, which is scheduled to be held in Amarillo on June 22, 2006.

Mr. D'Alonzo is a seasoned executive with experience in all major facets of pharmaceutical operations: sales and marketing, manufacturing, quality assurance, finance and licensing, and strategic planning. Mr. D'Alonzo served as President of Pharmaceutical Product Development, Inc., a multi-national clinical research organization with 3,000 employees operating in 14 countries and generating $300 million in revenues from analytical labs and Phase I, II, III and IV clinical trials. Previously, Mr. D'Alonzo was President of Genevec, Inc., a gene therapy biotech company with basic research programs in adenovirus and herpes virus vectors for gene delivery to cells. Before that, Mr. D'Alonzo was President of Glaxo, Inc., the U.S. unit of what is now Glaxo SmithKline plc.

Mr. Ulie, a Chartered Financial Analyst, has been in the investment field for more than 30 years, and is currently CEO of First Island Capital, Inc., a West Coast-based NASD broker-dealer firm. Mr. Ulie also serves as a director of a number of medical companies and has wide ranging experience in the investment community, having worked in investment banking, money management and research. Mr. Ulie was a Senior Managing Director for the Stanford Company, a NYSE member firm, an Associate Director of Bear Stearns & Co., where he worked in money management/brokerage, and has held positions with other firms including Oppenheimer & Co. Inc., Lehman Brothers Kuhn Loeb, and Fiduciary Counsel Inc.

ABI President Joseph Cummins said, "We are delighted to nominate both Tom D'Alonzo and Tom Ulie to our Board of Directors. In Tom D'Alonzo's case we welcome back a former Director whose experience in the pharmaceutical industry will doubtless prove to be of invaluable assistance to ABI. Tom Ulie, a major ABI shareholder, has a long and impressive background in the investment business. Importantly, both nominees have a great deal of public company and financial markets experience, which will be a key component in driving ABI to a new level of acceptance in the financial community."

About Amarillo Biosciences, Inc.

Amarillo Biosciences, Inc. is a U.S. biotechnology firm operating in global partnership with the Hayashibara Group, which also holds 15% of Amarillo Biosciences shares and has provided over $17.8 million in loans, grants and equity investments. The Company's primary focus is extensive and ongoing R&D into the use of low-dose, orally administered interferon as a treatment for a variety of conditions, including Sjogren's syndrome, Behcet's disease, idiopathic pulmonary fibrosis, hepatitis B, myeloproliferative diseases and opportunistic infections in patients who are HIV positive. In its 20-year history, ABI has invested nearly $37 million to establish oral interferon as a therapeutic agent. The majority of those funds were invested in clinical trials in an effort to achieve FDA approval for interferon. Additional information is available on the ABI web site at http://www.amarbio.com/.

Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance of oral interferon or the Company's other product candidates and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. In particular, see "Item 1. Description of Business" of the Company's Form 10-KSB for the year ended December 31, 2005.

Contact Information

  • Investor Relations:

    Philippe Niemetz
    PAN Consultants, Ltd.
    Tel: 800-477-7570
    Tel: 212-344-6464
    Fax: 212-618-1276
    e-mail:p.niemetz@panconsultants.com

    Joseph M. Cummins, DVM, PhD
    Amarillo Biosciences, Inc.
    Tel: 806-376-1741 x 13
    Fax: 806-376-9301
    e-mail:jcummins@amarbio.com